Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Medication Precertification Request

(All fields must be completed and legible for Precertification Review)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy, Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		DOB:
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	Email:
Patient Current Weight: _____ lbs or _____ kgs Patient Height: _____ inches or _____ cms			Allergies:

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured:

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured:

Medicare: ☐ Yes ☐ No If yes, provide ID #: **Medicaid:** ☐ Yes ☐ No If yes, provide ID #:

C. PRESCRIBER INFORMATION

First Name:		Last Name:		*(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.	
Address:			City:	State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	

Specialty *(Check one):* ☐ **Oncologist** ☐ **Hematologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for: ☐ **Darzalex Faspro (daratumumab and hyaluronidase-fihj) Dose:** _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: ☐ _____ **Secondary ICD Code :** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

For All Requests: (Clinical documentation required for all requests)

☐ **Multiple myeloma**

What is the prescribed regimen?

☐ Darzalex Faspro in combination with bortezomib, thalidomide, and dexamethasone
→ ☐ Yes ☐ No Is the patient eligible for autologous stem cell transplant?
☐ Yes ☐ No Will the requested medication be used as primary therapy?
☐ Yes ☐ No Will the requested medication be used for a maximum of 16 doses?

☐ Darzalex Faspro in combination with lenalidomide and dexamethasone
→ ☐ Yes ☐ No Is the patient eligible for autologous stem cell transplant?
☐ Yes ☐ No Will the requested medication be used as primary therapy?
☐ Yes ☐ No Has the patient received one or more prior therapies?

☐ Darzalex Faspro in combination with bortezomib, melphalan, and prednisone
→ ☐ Yes ☐ No Is the patient eligible for autologous stem cell transplant?
☐ Yes ☐ No Will the requested medication be used as primary therapy?

☐ Darzalex Faspro in combination with bortezomib and dexamethasone
→ ☐ Yes ☐ No Has the patient received at least one prior therapy?

☐ Darzalex Faspro in combination with carfilzomib and dexamethasone
→ ☐ Yes ☐ No Is the patient's disease relapsed or progressive?

Continued on next page

Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Medication Precertification Request

(All fields must be completed and legible for Precertification Review)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION ***(continued)*** – Required clinical information must be completed in its entirety for all precertification requests.

☐ Darzalex Faspro in combination with pomalidomide and dexamethasone
→ ☐ Yes ☐ No Has the patient received at least two prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent?

☐ Darzalex Faspro as a single agent
→ ☐ Yes ☐ No Has the patient received at least three prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent?
→ ☐ Yes ☐ No Is the patient double refractory to a proteasome inhibitor (PI) and an immunomodulatory agent?

For Continuation Requests: (Clinical documentation required for all requests)

☐ Yes ☐ No Has the patient experienced disease progression or unacceptable toxicity while on Darzalex Faspro?
→ Please select: ☐ Disease progression ☐ Unacceptable toxicity

H. ACKNOWLEDGEMENT

Request Completed By ***(Signature Required):*** _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.